Monday, March 23, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

What to know about nitrosamine, the cancer-causing ingredient behind Pfizer’s recent drug recalls

Several investigations in recent years have prompted the recall of prescription drugs contaminated with a potential carcinogen known as nitrosamine.

The latest recall related to nitrosamines, a class of compounds thought to cause cancer, came last week from Pfizer. On Wednesday, the pharmaceutical giant announced a voluntary recall of some shipments of blood pressure drugs.

Along with six lots of tablets branded as Accuretic, Pfizer recalled five lots of generic versions of the drug (quinapril and hydrochlorothiazide) after they were found to contain an unacceptable amount of N-nitroso-quinapril, a nitrosamine, according to the US Food and Drug Administration.

Source: Insider

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!